Posted 8th July 2020 by Joshua Sewell
Extracellular vesicles provide an exciting opportunity as a modality for non-invasive biomarkers, which may enable them to be used as biomarkers for tumour metastasis.
Posted 24th June 2020 by Joshua Sewell
We spoke with Dr David Guttery about his pioneering work using circulating tumour DNA to enable early detection, monitoring and therapeutic decision making for better patient outcomes in gynaecological cancers.
Posted 13th November 2019 by Joshua Sewell
This blog was published on Clarivate’s Cortellis blog. It is reproduced here with their kind permission.
A fascinating range of insights into the ways in which the immune system can be harnessed to fight cancer was provided by Global Engage’s Immuno-Oncology Research & Technology Series meeting held in October in London. The conference comprised five concurrent tracks covering cutting-edge developments in fields such as cell therapies, novel antibodies and neoantigens. Some of the highlights tracked by the Cortellis team are presented below.
Posted 17th July 2019 by Jane Williams
Anders Stahlberg works both in the academic setting as Associate Professor at the University of Gothenburg and in the clinical setting at Clinical Genetics & Genomics, Sahlgrenska University Hospital. Together with his colleagues, this means all aspects of circulating cell-free tumour DNA are covered; from basic science and development, understanding why and how liquid biopsies should be undertaken, to clinically focused questions that the patient will hopefully benefit from.
Ahead of the Liquid Biopsies Congress later this year, we spoke to him about his work.
Posted 19th June 2019 by Joshua Sewell
During my eight years at the Max Planck Institute for Molecular Genetics in Berlin, I led a protein technologies group. We developed a protein expression library, and then high-content protein arrays. In total, we made arrays with 10,000 different human proteins.
Posted 12th June 2019 by Joshua Sewell
When conducting an experiment to identify biomarkers, it is crucial to design the experiment properly. 80-90% of all biomarker populations for the last 20 years have not and cannot be reproduced, and the main reason that biomarkers fail is that these experiments are not designed properly. In this post, I will outline two ways in which experiments are poorly designed, and then outline the technological and methodological solution in a later blog.
Posted 3rd June 2019 by Joshua Sewell
There is a huge need to identify biomarkers to discern which metastatic colorectal cancer patients will benefit from treatment using Regorafenib. Despite being the latest approved drugs for the disease, Regorafenib has limited clinical efficacy and is associated with a number of side effects. However, a lot of patients are treated with Regorafenib as it is the only treatment available for patients who cannot receive anti-EGFR treatment due to K-RAS or BRAF mutation.